leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma says over-the-counter Relief & Go Pain Relief spray wins FDA approval to commence marketing

The pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD

InnoCan Pharma - Innocan Pharma Corporation says over-the-counter Relief & Go Pain Relief spray product receives technical validation and approval to commence marketing from FDA
About 1.5 billion people worldwide suffer from chronic pain and the treatment market could reach US$106 billion by 2024

Innocan Pharma Corporation (CSE:INNO) announced Monday that its over-the-counter Relief & Go Pain Relief spray product has received the US Food and Drug Administration's technical validation and approval to commence marketing.

Innocan's pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD, administered with a simple dose of spray, roll-on or lotion. The Relief & GO Pain Relief spray is designed to target pain-related muscle and provide relief for joint pain. 

"We are excited to receive the approval from the FDA to market our flagship pain relief product in the USA," Innocan CEO Iris Bincovich said in a statement. 

READ: Innocan Pharma director Bill Macdonald resigns as CBD company settles $50,000 debt

"This represents the company's ability to develop and practice breakthrough technologies to create new CBD based products for the growing pain relief market," she added.

About 1.5 billion people worldwide suffer from chronic pain and the treatment market could reach US$106 billion by 2024, according to reports.

The company, through its wholly-owned subsidiary Innocan Pharma Ltd in Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients. 

Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the coronavirus (COVID-19). 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

 

 

 

Quick facts: InnoCan Pharma

Price: 0.25 CAD

CSE:INNO
Market: CSE
Market Cap: $43.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma bring significant update on Injectable CBD delivery system...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has provided an update on their Injectable CBD delivery system that allows control release. Bincovich telling Proactive some of the recent works done to prove the efficacy of the project...

2 days ago

2 min read